MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Kodu・Aktsiate loetelu・VolitionRX Ltd

VolitionRX Ltd

Suletud

0.24 -4

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.24

Max

0.25

Põhinäitajad
By Trading Economics
Sissetulek	936K -5.4M
Müük	221K 627K
Kasumimarginaal	-857.414
Töötajad	75
EBITDA	1.3M -4.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+765.38% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-17M 29M
Eelmine avamishind	4.24
Eelmine sulgemishind	0.24

VolitionRX Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. dets 2025, 22:20 UTC

Suurimad hinnamuutused turgudel

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. dets 2025, 17:31 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. dets 2025, 16:30 UTC

Suurimad hinnamuutused turgudel

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. dets 2025, 15:19 UTC

Suurimad hinnamuutused turgudel

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. dets 2025, 15:17 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. dets 2025, 14:37 UTC

Suurimad hinnamuutused turgudel

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

1. jaan 2026, 23:35 UTC

Market Talk

Gold Rises Amid Geopolitical Risks -- Market Talk

1. jaan 2026, 21:29 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

1. jaan 2026, 21:29 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Sold Stake in JV to Tata Steel

1. jaan 2026, 21:28 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

1. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. jaan 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. dets 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. dets 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. dets 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. dets 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. dets 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. dets 2025, 17:16 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. dets 2025, 17:00 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. dets 2025, 15:57 UTC

Omandamised, ülevõtmised, äriostud

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. dets 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. dets 2025, 15:02 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. dets 2025, 14:40 UTC

Omandamised, ülevõtmised, äriostud

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. dets 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. dets 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Võrdlus sarnastega

Hinnamuutus

VolitionRX Ltd Prognoos

Hinnasiht

By TipRanks

765.38% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 765.38%

Kõrge 3 USD

Madal 1.5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi VolitionRX Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi VolitionRX Ltd aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.